At the "Healthy China 2030" and Big Health Industry Development seminar held during the China Development Forum 2026 annual meeting from March 22-23 in Beijing, Marc Casper, Chairman and CEO of Thermo Fisher Scientific, highlighted two core areas as particularly vital for the future development of China's healthcare industry: oncology diagnosis/treatment and addressing population aging. He stated that cancer is a pressing health challenge for China and the world, and a series of breakthroughs in science are profoundly changing the ways cancer is diagnosed and treated.
He explained that current molecular analysis technologies can already assist doctors in matching personalized treatment plans based on the specific drivers of a patient's tumor. Chinese researchers are combining advanced proteomics technologies with AI-driven analytical methods to discover novel biomarkers, enabling precise patient stratification for personalized treatment decisions. Casper expressed that as China's investments in exploring life sciences continue to materialize, future cancer care is expected to achieve earlier detection and more effective treatment. The medical field is rapidly transitioning towards precision medicine, an area where Thermo Fisher Scientific has deep expertise and is continuously accelerating the development of related technologies and applications.
Casper highly commended China's achievements in drug innovation, noting that China has become a global hub for pharmaceutical innovation, distinguished by its rapid innovation pace and strong scientific creativity. Breakthroughs by Chinese researchers in immunotherapy and next-generation cell therapies are progressing to international clinical trials, with discovered molecules playing significant roles in global drug development pipelines, becoming important drivers for improving patient lives worldwide.
He mentioned that in recent years, Chinese biotech companies have secured major global licensing agreements, including several multi-billion dollar deals in oncology, fully demonstrating the strength and maturity of China's innovation ecosystem and representing a significant evolution for China's pharmaceutical industry. Casper also pointed out that global corporate development faces complex challenges requiring expertise across regulatory domains, clinical operations, and quality standards. Sustained industry growth depends on collaborative frameworks that enhance international scientific cooperation and facilitate the efficient cross-border flow of innovative成果.
Casper emphasized the critical importance of international collaboration, stating that no single company or country can tackle the many challenges in healthcare alone. Global health progress relies on an interconnected innovation ecosystem. Thermo Fisher Scientific is proud to be a trusted partner for many companies, committed to bringing innovations to global markets. The company provides comprehensive technical services from early-stage research and clinical trial implementation to scaled-up manufacturing, helping innovators efficiently and rigorously advance R&D and industrialization processes. It also supports diagnostic and advanced therapy development projects, assisting companies in meeting international standards to accelerate global access to innovative treatments.